deferasirox has been researched along with sulbactam in 3 studies
Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (sulbactam) | Trials (sulbactam) | Recent Studies (post-2010) (sulbactam) |
---|---|---|---|---|---|
832 | 136 | 572 | 1,844 | 297 | 488 |
Protein | Taxonomy | deferasirox (IC50) | sulbactam (IC50) |
---|---|---|---|
Beta-lactamase | Escherichia coli | 6.2 | |
Beta-lactamase | Shouchella clausii | 0.075 | |
Beta-lactamase | Pseudomonas aeruginosa | 0.37 | |
Beta-lactamase | Pseudomonas aeruginosa | 3 | |
Beta-lactamase | Aeromonas allosaccharophila | 4 | |
Beta-lactamase | Staphylococcus aureus | 6.5 | |
Beta-lactamase | Enterobacter cloacae | 1.4 | |
Beta-lactamase TEM | Escherichia coli | 4.3 | |
Beta-lactamase | Acinetobacter pittii | 1.12 | |
Beta-lactamase | Acinetobacter pittii | 7.758 | |
Beta-lactamase | Pseudomonas aeruginosa | 3 | |
Beta-lactamase | Escherichia coli | 2.4 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Brewster, JT; Han, HH; He, XP; Hu, XL; Lynch, VM; Mangel, DN; Sedgwick, AC; Sessler, JL; Shang, Y; Snelson, DW; Steinbrueck, A; Tian, H; Yan, KC | 1 |
3 other study(ies) available for deferasirox and sulbactam
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties.
Topics: Alkaline Phosphatase; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Biomarkers; Cefoperazone; Deferasirox; Fluorescent Dyes; Light; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microscopy, Confocal; Microscopy, Fluorescence; Pseudomonas aeruginosa; Sulbactam | 2021 |